Weight gain after stopping Eli Lilly's new obesity treatment should help, not hurt the stock
Data showing weight gain after stopping Eli Lilly's Zepbound was positive despite earlier selling pressure, Jim Cramer said Tuesday.
Aliver
0
75
David Ricks, CEO, Eli Lilly
Scott Mlyn | CNBC
Some Eli Lilly investors appear concerned about clinical trial data that showed patients regained weight after they stopped taking the company's obesity drug Zepbound. The situation seems rather clear-cut to us: It's no reason to sell.
